CA3201032A1 - Y box binding protein 1 inhibitors - Google Patents

Y box binding protein 1 inhibitors

Info

Publication number
CA3201032A1
CA3201032A1 CA3201032A CA3201032A CA3201032A1 CA 3201032 A1 CA3201032 A1 CA 3201032A1 CA 3201032 A CA3201032 A CA 3201032A CA 3201032 A CA3201032 A CA 3201032A CA 3201032 A1 CA3201032 A1 CA 3201032A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201032A
Other languages
English (en)
French (fr)
Inventor
Sanjay V. Malhotra
Dhanir TAILOR
Arpit DHEERAJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Leland Stanford Junior University
Original Assignee
Oregon Health and Science University
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, Leland Stanford Junior University filed Critical Oregon Health and Science University
Publication of CA3201032A1 publication Critical patent/CA3201032A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3201032A 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors Pending CA3201032A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121674P 2020-12-04 2020-12-04
US63/121,674 2020-12-04
US202163256609P 2021-10-17 2021-10-17
US63/256,609 2021-10-17
PCT/US2021/061906 WO2022120242A1 (en) 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors

Publications (1)

Publication Number Publication Date
CA3201032A1 true CA3201032A1 (en) 2022-06-09

Family

ID=81853609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201032A Pending CA3201032A1 (en) 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors

Country Status (6)

Country Link
US (1) US20240016784A1 (https=)
EP (1) EP4255426A4 (https=)
JP (1) JP2023552368A (https=)
AU (1) AU2021391931A1 (https=)
CA (1) CA3201032A1 (https=)
WO (1) WO2022120242A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4554587A2 (en) * 2022-07-12 2025-05-21 Oregon Health & Science University Enantiomer of azopodophyllotoxin derivative su056

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170342086A1 (en) * 2015-02-26 2017-11-30 Ajay Kumar Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
US11098052B2 (en) * 2016-03-02 2021-08-24 Arizona Board Of Regents On Behalf Of Arizona State University 4-azapodophylotoxins compounds
US11771692B2 (en) * 2018-03-13 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University N-hydroxyethyl didehydroazapodophyllotoxins as GBP1 inhibitors and methods of overcoming treatment resistance in cancer
CN116761602A (zh) * 2020-12-04 2023-09-15 俄勒冈健康与科学大学 Y盒结合蛋白质1抑制剂

Also Published As

Publication number Publication date
JP2023552368A (ja) 2023-12-15
EP4255426A4 (en) 2024-10-23
WO2022120242A1 (en) 2022-06-09
US20240016784A1 (en) 2024-01-18
EP4255426A1 (en) 2023-10-11
AU2021391931A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20240082218A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
US11377451B2 (en) Compositions and methods for treating cancer
ES2732026T3 (es) Sal de adición de ácido de un compuesto inhibidor de Trk
US9073916B2 (en) Prodrug forms of kinase inhibitors and their use in therapy
AU2013214783B2 (en) CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
ES2780382T3 (es) Derivados de pirazolopirimidina
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
AU2010292225A1 (en) N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
AU2016324158A1 (en) PCNA inhibitors
US20210261516A1 (en) Myc g-quadruplex stabilizing small molecules and their use
Mehrling et al. The alkylating-HDAC inhibition fusion principle: taking chemotherapy to the next level with the first in class molecule EDO-S101
ES2762641T3 (es) Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina
JP6472096B2 (ja) 癌を処置するための新規方法
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
CN108472376A (zh) 用于治疗癌症的合理组合疗法
US20240016784A1 (en) Y box binding protein 1 inhibitors
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
CA3001204C (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
CN116761602A (zh) Y盒结合蛋白质1抑制剂
ES3034869T3 (en) Tg02 for use in treating gliomas in pediatric subjects
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
US20240400572A1 (en) Compounds and methods for treating cancers that are mgmt deficient regardless of mmr status
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer
Bofill et al. NME Digest

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251120

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260119

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260119

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122